Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;42(10):1269-1273.
doi: 10.1007/s10096-023-04660-3. Epub 2023 Sep 7.

Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases

Uğur Önal  1   2 , Deniz Akyol  3   4 , Arda Kaya  3 , Dilşah Başkol  3 , Buse Kenanoglu  3 , Gamze Şanlıdağ  3 , Ayşe Uyan Önal  3   5 , Cansu Bulut Avşar  3   6 , Merve Mert  3 , Seichan Memetali  3 , Hüseyin Aytaç Erdem  3 , Devrim Bozkurt  7 , Adnan Şimşir  8 , Osman Bozbıyık  9 , Ümit Kahraman  10 , Erkin Özgiray  11 , Pervin Korkmaz  12 , Feriha Çilli  13 , Hüsnü Pullukçu  3 , Tansu Yamazhan  3 , Meltem Işıkgöz Taşbakan  3 , Bilgin Arda  3 , Sercan Ulusoy  3 , Oğuz Reşat Sipahi  3   14
Affiliations

Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases

Uğur Önal et al. Eur J Clin Microbiol Infect Dis. 2023 Oct.

Abstract

Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.

Keywords: Bacteremia; Carbapenem-resistant Klebsiella pneumonia; Double carbapenem therapy.

PubMed Disclaimer

References

    1. Tamma PD, Aitken SL, Bonomo RA (2022) Infectious Diseases Society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious Diseases Society of America 2022; Version 1.1. https://www.idsociety.org/practice-guideline/amr-guidance/ . Accessed 28 April 2023
    1. Moody RO (2021) The effect of double-carbapenem therapy on mortality rates and microbiological cure rates in patients diagnosed with carbapenem -resistant Klebsiella pneumoniae infections in comparison to monotherapy and currently used combinations of antibiotics: a meta-analysis. J Med Res Innov 5:e000243 - DOI
    1. Önal U, Sipahi OR, Pullukçu H (2020) Retrospective evaluation of the patients with urinary tract infections due to carbapenemase producing Enterobacteriaceae. J Chemother 32:15–20 - DOI - PubMed
    1. Önal U, Akyol D, Mert M (2022) Carbapenem-resistant Gram-negative pathogens associated with septic shock: a review of 120cases. J Chemother 34:436–445 - DOI - PubMed
    1. Yy Li, Wang J, Wang R (2020) Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. BMC Infect Dis 20:408 - DOI

LinkOut - more resources